SOLICITATION NOTICE
66 -- Brand name only - Becton Dickson Antibodies - Package #1 - Package #2
- Notice Date
- 3/23/2016
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 5601 Fishers Lane, 3rd Floor MSC 9822, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- RFQ-RML-E-1782798
- Archive Date
- 4/5/2016
- Point of Contact
- Jesse Weidow, Phone: 4063759783, Barbara Horrell, Phone: 406-363-9489
- E-Mail Address
-
weidowjd@niaid.nih.gov, horrellb@niaid.nih.gov
(weidowjd@niaid.nih.gov, horrellb@niaid.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Detailed posting Terms and Conditions Justification for Other than Full and Open Competition: Brand-Name at or Below the Simplified Acquisition Threshold Project Title: Brand Name - Becton Dickson Antibodies I.Identification of the agency and contracting activity DHHS, NIH, NIAID/DIR/LID/ Viral Pathogenisis & Evolution Section Requestors name: Tyler Bristol Requestors phone number: 301-761-6268 Requestors email address: tyler.bristol@nih.gov Address of the requesting lab/office: Bldg 33 Room 3W10A, Bethesda, MD II.Description of the project, and supplies or services required to meet the agency's needs (including the estimated value) A.Type of action: (check the appropriate box) ☒ New requirement ☐ Follow-on •Name of the previous contractor(s): •Sequence number, if available: •Was the initial and any subsequent awards competed? ☐ Yes ☐ No B.AMBIS Sequence number for this requirement: 1782798 C.Total estimated dollar value of the requirement (including options, if applicable): $37,333.10 D.Period of performance, inclusive of options: Does not apply - no POP E.Project Background: The Viral Pathogeneses and Evolution Section (VPES) within the Laboratory of Infectious Disease (LID) conducts research directed towards defining the cause of epidemiology of influenza viral infections and developing means for their control. VPES engages in a wide range of research activities that extends from clinical virology to molecular characterization of highly virulent influenza viruses that cause severe acute disease of the respiratory tracts in animal models to the development of human challenge models, novel vaccines and antiviral drugs and vaccines. F.Description of the supplies/services to be purchased: #DESCRIPTION CATALOG QTY 1CD45RA PE-Cy7 L48 100 Tests RUO/GMP - 337167 00382903371679 - 4 each 2CD10 FITC HI10a 50 Tests RUO/GMP - 340925 00382903409259 - 4 each 3CD19 APC-H7 SJ25C1 ASR643078 - 00382906430786 - 4 each 4CD19 PerCP-Cy5.5 SJ25C1 50 Tests RUO/GMP - 340951 00382903409518 - 4 each 5CD25 PE 2A3 50 Tests RUO/ GMP - 341009 00382903410095 - 4 each 6CD38 APC HB7 100 Tests RUO/GMP - 340439 00382903404391 - 6 each 7CD4 PerCP-Cy5.5 SK3 RUO/ GMP - 341654 00382903416547 - 11 each 8Hu CD24 PE ML5 100Tst - 555428 00382905554285 - 2 each 9Hu CCR4 PE-Cy7 1G1 100ug - 557864 00382905578649 - 4 each 10Hu CD11C PE-Cy7 B-LY6 50Tst - 561356 00382905613562 - 8 each 11Hu CD123 PerCP-Cy5.5 7G3 100Tst - 558714 00382905587146 - 1 each 12Hu CD127 Alexa 647 HIL-7RM21 25Tst - 560905 00382905609053 - 15 each 13Hu CD14 Horizon V450 MfP9 120Tst - 560349 00382905603495 - 3 each 14Hu CD16 APC B73.1 50Tst - 561304 00382905613043 - 4 each 15Hu CD183 PE 1C6/CXCR3 100Tst - 557185 00382905571855 - 1 each 16Hu CD196 PE-Cy7 11A9 50Tst - 560620 00382905606205 - 4 each 17Hu CD197 (CCR7) PE 150503 100Tst - 560765 00382905607653 - 2 each 18Hu CD20 APC-H7 2H7 50Tst - 560734 00382905607349 - 15 each 19Hu CD27 PE-Cy7 M-T271 50Tst - 560609 00382905606090 - 4 each 20Hu CD3 APC-H7 SK7 100Tst - 560176 00382905601767 - 4 each 21Hu CD3 Horizon V450 UCHT1 120Tst - 560365 00382905603655 - 12 each 22Hu CD39 FITC TU66 100Tst - 561444 00382905614446 - 2 each 23Hu CD45RO APC-H7 UCHL1 50Tst - 561137 00382905611377 - 8 each 24Hu CD56 PE B159 100Tst - 555516 00382905555169 - 4 each 25Hu CD8 APC-H7 SK1 100Tst - 560179 00382905601798 - 8 each 26Hu CXCR5 Alexa 488 RF8B2 100ug - 558112 00382905581120 - 1 each 27Hu HLA-DR HorizonV500 G46-6 100Tst - 561224 00382905612244 - 29 each 28Hu IgD Horizon V500 IA6-2 50Tst - 561490 00382905614903 - 8 each III.Identification of the statutory authority permitting other than full and open competition (SELECT ONE) ☒41 USC 3304(a)(1) and FAR Part 6.302-1: Only one responsible source / Brand Name ☐FAR Part 8.405-6: Federal Supply Schedule (FSS), limited competition / Brand Name Important Note: The statutory authority listed below will rarely ever be used in NIH. Before selecting this authority, please ensure that you have read and understood the citation and discussed it with the cognizant Contracting Officer. ☐41 USC 3304(a)(5) and FAR Part 6.302-5: Authorized or required by statute / Brand Name IV.Demonstration that the proposed brand name product's salient charictoristics (specific features, qualities and/or the nature of the acquisition) requires use of the authority cited. NIH has been using specific regeants, antibodies and biologicals from Beckman Dickson that have been utilized for several years. These experiments are ongoing and require the use of the same type of regeants, antibodies and biologicals for continuity and reliability of data. Changing to a different type of material at this stage in the testing/experiments would be disastrous, causing pervious work to be invalidated and most importantly the setback would cause unnecessary delays and would increase project costs. With that being said, the salient requirements of numerous research projects must be maintained. The project officer and the Contracting Officer have determined that only one brand-name source and no other brands or services will satisfy agency requirements. V.Determination by the Contracting Officer that the anticipated cost/price to the Government will be fair and reasonable Price reasonableness determination will be included in the acquisition file. VI.Certification This is to certify that the justification for the proposed acquisition has been reviewed and that to the best of my knowledge and belief the information and/or data provided to support my request and CO approval of is accurate and complete.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/AMOB/RFQ-RML-E-1782798/listing.html)
- Place of Performance
- Address: 33 North Drive, Bethesda, Maryland, 20814, United States
- Zip Code: 20814
- Zip Code: 20814
- Record
- SN04060073-W 20160325/160323235440-cbc7f072365dd3fd19767b611e1b8a9f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |